hpv19 + 5-fluorouracil + oxaliplatin + leucovorin

This is a **combination regimen** composed of hpv19 (not a standard drug; likely a code for a clinical candidate or experimental immunotherapy), 5-fluorouracil, oxaliplatin, and leucovorin. 5-Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. Oxaliplatin is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis, and leucovorin (folinic acid) enhances the cytotoxic effect of 5-FU by stabilizing the inhibition of thymidylate synthase. The regimen of 5-fluorouracil, oxaliplatin, and leucovorin is well established as the FOLFOX protocol, primarily used in colorectal and some gastric cancers[2][4]. The addition of "hPV19" is not standard; it could refer to an investigational immunotherapy or vaccine targeting human papillomavirus (HPV), though no widely recognized pharmaceutical by that name exists as of September 2025.